Results 41 to 50 of about 29,788 (124)

Histopathological Study of Ovarian Lump and Serum Tumor Marker Ca 125 estimation as a Screening Tool

Journal of Nobel Medical College, 2018
Background: Ovarian tumor is the fourth commonest cancer in female in Nepal. About 80% is benign and 20% of these tumors are malignant. Due to its complex nature, vagueness and non-specificity of the symptoms it produces, the ovarian neoplasm can mislead
Manish Kumar Das, Sita Ghimire
doaj   +1 more source

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

MedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta, Ramakrishna Vadde, Ganji Purnachandra Nagaraju   +2 more
wiley   +1 more source

Social, Genetics and Histopathological Factors Related to Titin (TTN) Gene Mutation and Survival in Women with Ovarian Serous Cystadenocarcinoma: Bioinformatics Analysis

, 2023
Several factors may increase the risk of development of ovarian cancer. In this study, we investigated the relationship between social, genetic, and histopathologic factors in women with ovarian serous cystadenocarcinoma and titin (TTN) mutations ...
Eric Renato Lima Figueiredo, Manuela Trindade Almeida, Lucélia Inoue Bispo Teixeira, Mariusa Fernandes De Farias, João Simão de Melo-Neto, Ediane Nunes De Araújo, Edila Monteiro De Andrade, Fabiana de Campos Gomes, Carlos Diego Lisbôa Carneiro, Helana Augusta Andrade Leal Dias, Natália Albim Linhares, Yago Dos Santos Pereira, Gabriel Mácola De Almeida, Natasha Lima Da Fonseca   +13 more
core   +1 more source

The intratumoral microbiota biomarkers for predicting survival and efficacy of immunotherapy in patients with ovarian serous cystadenocarcinoma

Journal of Ovarian Research
Background Ovarian serous cystadenocarcinoma, accounting for about 90% of ovarian cancers, is frequently diagnosed at advanced stages, leading to suboptimal treatment outcomes.
Hao Qin, Jie Liu, Yi Qu, Yang-Yang Li, Ya-Lan Xu, Yi-Fang Yan   +5 more
doaj   +1 more source

Clinicopathologic study of malignant ovarian tumors: A study of fifty cases

Medical Journal of Dr. D.Y. Patil University, 2017
Background: Malignant ovarian tumors have worst prognosis among all gynecological malignancies and highest case fatality rate. There is a steady increase in the age-standardized incidence rate in India.
Shirish S Chandanwale, Rahul Jadhav, Ruby Rao, Piyusha Naragude, Sunita Bhamnikar, Jehan Nizam Ansari   +5 more
doaj   +1 more source

NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2

Cancer Science, Volume 117, Issue 10, Page 2803-2818, October 2026.
Copy number variation analysis in The Cancer Genome Atlas identified NTAQ1 as a potential driver of HCC progression. NTAQ1 accelerates tumor growth by promoting the degradation of the tumor suppressor protein PRDM2, thereby impairing DNA repair and suppressing apoptosis. These findings indicate that NTAQ1 could be a valuable target for the treatment of
Tomohiko Ikehara, Hajime Otsu, Taro Tobo, Kiyotaka Hosoda, Tadashi Abe, Masahiro Hashimoto, Yusuke Nakano, Katsushi Dairaku, Yuya Ono, Yuki Miyata, Chihiro Matsumoto, Takanari Tatsumi, Satoshi Higuchi, Takashi Ofuchi, Akinori Tsujimoto, Yuki Ando, Qingjiang Hu, Yusuke Yonemura, Akira Shimizu, Takaaki Masuda, Yuji Soejima, Koshi Mimori   +21 more
wiley   +1 more source

Pancreatic cystadenoma and cystadenocarcinoma

, 1984
Cystadenomas and cystadenocarcinomas are rare but not exceptional tumours of the pancreas. In this report six cases are added to the more than 300 cystadenomas and over 100 cystadenocarcinomas reported in the literature.
von Segesser, L., Rohner, A.
core   +1 more source

Triazole‐Linked Pyrimidine Nucleoside Dimers: Design, Synthesis, and Applications in Medicinal and Nucleic Acid Chemistry. Part IV

Chemical Biology &Drug Design, Volume 108, Issue 4, October 2026.
A series of 18 pyrimidine nucleoside dimers analogues with a short 1,4‐disubstituted 1,2,3‐triazole linkage were synthesized using a click chemistry approach (CuAAC). Analysis of the obtained products was conducted utilizing 1D/2D NMR spectroscopy (1H, 13C, 19F, 15N, and 29Si), mass spectrometry (ESI‐MS), and high‐performance liquid chromatography ...
Dagmara Baraniak, Dariusz Wawrzyniak, Daniel Baranowski   +2 more
wiley   +1 more source

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, Volume 20, Issue 9, Page 2220-2242, September 2026.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source

Malignant mixed epithelial tumour of ovary-serous papillary cystadenocarcinoma and transitional cell carcinoma with tubo-ovarian torsion: A rare tumour with rare presentation [PDF]

, 2013
Ovarian torsion can be associated with various pathophysiological factors. Most commonly, benign epithelial ovarian tumours present with torsion. We present an unusual case of mixed malignant epithelial ovarian tumour with a predominant component of high-
Nor Fathihah binti Mamat
core   +1 more source